



JP Morgan Healthcare Conference

January 9th, 2023

Matt Trerotola - Chief Executive Officer

Ben Berry - Chief Financial Officer

Derek Leckow - Vice President, Investor Relations

enovis™

Creating Better Together™

Forward-Looking Statement Disclaimer

FORWARD -LOOKING STATEMENTS

This presentation includes forward-looking statements, including forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Such forward-looking statements include, but are not limited to, statements concerning Enovis' plans, goals, objectives, outlook, expectations and intentions, including the anticipated benefits of our recently completed separation of Enovis' fabrication technology and specialty medical technology businesses (the "Separation") and other statements that are not historical or current fact. Forward-looking statements are based on Enovis' current expectations and involve risks and uncertainties that could cause actual results to differ materially from those expressed or implied in such forward-looking statements. Factors that could cause Enovis' results to differ materially from current expectations include, but are not limited to, risks related to the impact of the COVID-19 global pandemic, including the scope and duration of the outbreak, the rise, prevalence and severity of variants of the virus, material delays and cancellations of medical procedures, the nature and effectiveness of actions and restrictive measures by governments, businesses and individuals in response to the situation, and their impact on the global and regional economies, financial markets, creditworthiness and financial viability of customers, and overall demand for our products; the war in Ukraine and escalating geopolitical tensions as a result of Russia's invasion of Ukraine; macroeconomic conditions, including the impact of increasing inflationary pressures; supply chain disruptions; the potential to incur significant liability if the Separation is determined to be a taxable transaction; the ability to realize the anticipated benefits of the Separation, the financial and operating performance of the company following the Separation; other impacts on Enovis' business and ability to execute business continuity plans; and the other factors detailed in Enovis' reports filed with the U.S. Securities and Exchange Commission (the "SEC"), including its most recent Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q under the caption "Risk Factors," as well as the other risks discussed in Enovis' filings with the SEC. In addition, these statements are based on assumptions that are subject to change. This presentation speaks only as of the date hereof. Enovis disclaims any duty to update the information herein.

Key Takeaways

- Foundation in attractive orthopedic market with favorable market trends
 - Unique MedTech player with two strong segments and proven business system
 - Clear strategy and momentum for HSD organic growth fueled by innovation
 - Significant margin improvement path through mix, productivity and scale
 - Acquisition opportunities and ample capital to accelerate growth and compound value
 - Demonstrated track record and strong progress toward strategic goals
-



enovis

Creating Better Together™

ENOV
LISTED
NYSE

enovis

Enovis™ is a medical technology company focused on developing clinically differentiated solutions that generate measurably better patient outcomes and transform workflows.

Powered by a culture of continuous improvement, extraordinary talent and innovation, we 'create better together' by partnering with healthcare professionals.

Our extensive range of products, services and integrated technologies fuels active lifestyles.



#CreatingBetterTogether

Enovis: An Innovation and Growth Driven MedTech Company

Revenue and Segment Mix

\$1.6b

TTM¹



Two Attractive Business Segments

Fast growing reconstructive (Recon) platform

- DJO Surgical DD growth engine in US, leading in Shoulder and rapid adoption in Knee & Hip
- Globalized footprint and offering through acquisition of Mathys
- Expansion into attractive Foot & Ankle market in 2021


Global leader in prevention & recovery (P&R)

- Global leader in rigid bracing and soft goods
- Reshaping care path with MotionMD® and MotionIQ™ digital solutions
- Technology leader in recovery sciences with broad offering in advanced rehabilitation modalities

Positioned for significant growth and value creation

Addressing Large, Attractive Market

Enovis competes in half of the **\$53B Orthopedics market** and “touches” nearly all



Market Growth Trends Provide Runway



Aging but active population, rising obesity



Transitioning to outpatient care




Innovation improving the quality of care

Enovis is well-positioned in segments with strong long-term growth drivers

Established Brands and Accelerating Innovation

Prevention & Recovery Segment



#1
Globally in
Bracing

#1
Globally in
Rehab

#2
In Bone
Stimulation



DonJoy®



Aircast®




Chattanooga®



LiteCure®

Reconstructive Segment



DD
Organic Growth

#3
In US
Shoulder



Altivate®



Empowr Dual Mobility™




Empowr®



DynaNail™

Market leading position in P&R and fast-growing Recon products


Uniquely Positioned Across Full Ortho Care Continuum



Leveraging broad and deep market access and technology for strategic advantage

Scaled and Agile in Fragmented Industry

Competitive Ortho Landscape



Enovis is positioned for share gain, scale, and expansion

Strong Leadership Team, Deep MedTech Experience

Board of Directors



Mitch Rales
Chairman, Colfax,
DanaHER Co-
Founder



Matt Trerotola
CEO



Brady Shirley
President & COO



Barbara Bodem
Former SVP & CFO
of Hillrom



Liam Kelly
CEO of Teleflex
Incorporated



Angie Lalor
Former SVP of HR,
DanaHER, 3M



Phil Okala
COO, UPenn Health
Systems



Christine Ortiz
Prof. of Materials
Sciences and
Engineering, MIT



Clay Perfall
Operating
Executive, Tailwind
Capital



Rajiv Vinnakota
President, Institute
for Citizens &
Scholars



Sharon Wienbar
Former Partner,
Scale Venture
Partners

Enovis Senior Leadership Team



Matt Trerotola
CEO



Brady Shirley
President & COO



Ben Berry
EVP & CFO



Dan Pryor
EVP BD, Strategy



Patty Lang
CHRO



Brad Tandy
General Counsel



BIOMET

Strong Board and Leadership Team

Proven and Powerful Business System

Our Enovis **Growth eXcellence** business system is a set of **tools, processes, and culture**, incorporating continuous improvement to **drive and fuel growth**



Recent Activity

>40% reduction in recordable safety incidents


Step-change bracing customer service improvement

>100% improvement in shipping productivity in largest DC

EGX supporting growth acceleration and margin improvement

Establishing A High-Value MedTech Growth Company

Enovis Sales Performance & Goals




Clear path to \$2B and beyond with HSD organic growth and expanded margin profile

Strategy for Compounding Shareholder Value

Strategic Pillars...



...enabled by:



Shaping P&R Platform for Sustained MSD Growth

Re-establishing Strong Innovation Engine



2018

7%

2021

15%

Vitality¹ Index

Connecting Workflows with Digital Healthcare & Connected Medicine



Launched connected knee brace and sleeve in 2022

Investing in Attractive Rehab/Recovery Modalities

LiteCure™ Laser



2X Expansion in direct sales team

P&R Growth Has Stabilized


Stabilization Efforts

Re-established customer service levels

Increased vitality

Leveraging clinic workflow position and channel strength for share gains

Organic Sales Growth¹



Investment and improvements driving sustained above-industry growth

Rapidly Expanding High Growth & Margin Recon Platform

Leverage Demonstrated Outcomes



Altivate Reverse® Shoulder:

Breakthrough in range of motion



EMPOWR 3D Knee®:

breakthrough in natural kinematics

Continue Pace of Innovation

Expansion in product bag penetration:

~65% to ~75%

Launch enabling technology:

e.g. AR, CAS/Robotics



Win in the High Growth ASC

Leverage enabling technologies:

e.g. ARVIS®, ADAPTABLE®



Continuum of care coverage:

Pre, intra & post op offerings

Products aligned to favorable patient profiles

Grow & Scale Foot & Ankle

Launch innovative technologies:

e.g. DynaNail®, Arsenal Foot Plating System™



Modernize STAR™ ankle:

Patient Specific Instrumentation & Surface enhancements (e+ poly)



Expand Geographically

Mathys acquisition:

Nearly doubles addressable market and expands portfolio



Cross-selling opportunities:

Altivate® & EMPOWR® expansion




Recon Double-Digit Growth Formula

	<u>% of Recon Market</u>	<u>Market Growth¹</u>	<u>Projected Growth vs. Market</u>	<u>Growth Projection</u>	<u>2022 9M</u>
US Shoulder	~30%	7-8%	~2x	12 – 15%	13%
US Hip / Knee	~30%	3-4%	3-5x	10 – 15%	16%
Foot / Ankle	~10%	6-7%	2-3x	15 – 18%	8%
Int'l Recon	~30%	4-5%	2-3x	7 – 10%	11%
		<div>5-6% WAMGR</div>	<div>2-3X Market Growth</div>	<div>10-15%</div>	11%

Clear track record and trajectory for sustained double-digit organic growth


Fast-Growing Recon Business with Proven Playbook

US Shoulder Revenue



- **2X market growth** led by Altivate Reverse and accelerating Altivate Edge anatomic stemless
- **Proven MatchPoint® pre-operative plan and PSI system** in 35%+ of procedures

US Hip / Knee Revenue



- **3-5X market growth** powered by Empowr3D® Knee and Taperfill® Hip Stem
- **Great implants and enabling technologies** for ASC

Best-in-Class medical education across segments

Unparalleled KOL leadership team

Aggressive NPI cadence


Sustained strong DD growth across segments

Computer Assisted Surgery (CAS) Strategy

Anatomically distinct

Suite of offerings uniquely tooled to each anatomy

Match Point System™



Match Point™ System used in ~30% of Enovis shoulder cases



Best-in-class Pre-Op Planning & PSI¹ for Total Ankle



Unique guidance platform leveraging AR

Spanning entire workflow

End-to-end set of integrated components that can also be used on a standalone basis

Pre-Op / Patient Specific Instrumentation

Intra-Operative Imaging

Surgical Guidance / Robotics

Platform purpose-built for ASC

Optimized for ASC success – effective, efficient and affordable



Low capital costs



Time and Space Efficient




Micro footprint

Enovis enabling technologies will provide a flexible and scalable approach

Expanding Margins with Clear Strategy & EGX

aEBITDA Margin (%)

>50bps per year




Margin Drivers

- Mix benefits generated by growth in Recon
- Scale and synergy from recent acquisitions
- Operating leverage from growth, EGX productivity, COVID recovery and disciplined price/cost management

Continuous margin improvement leveraging growth and EGX

Robust M&A Opportunities to Accelerate Growth



Acquisition Criteria

- Fuels growth
- Improves gross margin
- Accelerates strategy
- Expands market reach
- Creates scale

Recent M&A Successfully Reshaping Our Business

Entered Foot & Ankle

- >\$1B Market
- HSD growth category
- Fragmented competition

**MedShape® /
Trilliant®**



AR Surgical Platform

- Next Gen total joint arthroplasty system
- Footprint and cost positioned for ASC

Arvis™ AR



ASC Solutions

- Double digit procedural volume growth
- Provides Surgical assistance

ADAPTABLE®



High Growth Modalities

- HSD growth category
- Synergy opportunities
- Expanded applications

LiteCure™ Laser



Geographical Expansion

- Drives growth outperformance
- Increased scale benefits
- Direct market penetration



DD+

Organic Growth

Accretive

Gross Margins

Ability to

Scale

~1.0x net leverage and ~\$1b of investment capacity...ample resources to support future growth

Key Takeaways

- Foundation in attractive orthopedic market with favorable market trends
 - Unique MedTech player with two strong segments and proven business system
 - Clear strategy and momentum for HSD organic growth fueled by innovation
 - Significant margin improvement path through mix, productivity and scale
 - Acquisition opportunities and ample capital to accelerate growth and compound value
 - Demonstrated track record and strong progress toward strategic goals
-



Creating Better Together™